The Public Face of Sulzer Medica
Sulzer Medica is one of Europe's leading medical device firms. But during the 1990s, though it grew nicely, it still trailed other, US-based multi-national device firms. That was because the company had struggled with product development and had no publicly-traded stock with which to acquire new businesses. Now fresh from a successful IPO, Suler is ready to play by a whole new set of rules.
You may also be interested in...
The once consolidating orthopedic implant business is, if anything, going in the opposite direction, given the decisions this week by parents of two of the leading companies to create stand-alone companies of their orthopedic businesses. Bristol-Myers confirmed what had been rumored for months: that it will spin off its Zimmer orthopedics business into a public company rather than sell the company to some other player. Earlier, Sulzer announced that it plans to spin off its medical device business, Sulzer Medica, in response to pressure from a large investor who was concerned about the industrial giant's declining stock performance. But these individual deals also represent a surprising industry turnaround--the consolidation of two years ago has largely stabilized pricing, allowing independent companies to thrive once again.
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
Yuyao YiJia Daily Chemical told FDA placed all drugs it manufactures on import alert in September because its methods and controls for manufacturing OTC sanitizers and other products do not appear to conform to current drug GMPs.